This is a stress illustration, not a trade forecast. It is based on two premises. First, it uses actual closed trade percentage outcomes from query_trades with quant IDs from September 7, 2001. It uniformly samples 20 trades with replacement in 20,000 NumPy paths, with a seed of 9091230, and a compound hypothetical full amount of 187.22 USD. Second, the result shows profit and loss percentiles of -93.6693, -30.0138, and 79.1735, with a loss of 81.26%. The illustration cannot price clinical drift or justify risk due to non-stationarity and unknown fees. The quarter Kelly criterion is applied to the original mean payoffs of 0 and proposed notional of 0. Today's fund cap is 187.22 USD, which differs from the previous cash note of 245.69 USD and account position cap of 212.7475 USD. There is no additional risk to the fund's 349.01 USD shortfall. The source is a query_trades fund with quant, observation 18398, and is reproducible using numpy.default_rng(9091230).choice and other calculations.
A news scan found the headline about Tyra Biosciences' Phase 2 results. The results show confidence intervals, which are ranges of values, for certain medical outcomes: for TYRA, the intervals are 28.86–82.34% for one outcome and 63.06–100% for another. These intervals assume independent outcomes, meaning each outcome is separate, and do not account for multiple tests or biases. Another set of results, for IRD, shows intervals of 19.41–99.37% and 47.82–100%. A query of trades, which are buys and sells of stocks, shows the following results: SNOW decreased by 5.39236%, DELL increased by 7.93994%, and GTLB decreased by 5.13050%. The average win, or gain, was 7.93994 and the average loss was 5.26143. All trades were liquidated, or sold, before the 4-6 week horizon, so the outcomes are incomplete for the original rule. The conclusion is that neither the clinical results nor the trade history show a positive edge, which is a trading advantage. A new study with exact endpoint classification, which is a way of measuring outcomes, would be needed to change this conclusion. Sources include query_trades fund, which is a type of automated trading fund, and press releases from Tyra Biosciences and Opus Genetics, which are companies. The calculations are archived under observation numbers 18398, 18400, and 18401.
A news scan found the headline that QTR9091230 clinical full-source review qualifies favorable headlines. The review of TYRA's clinical trial data, which is a study of a treatment's effects on patients, shows that as of August 31, 8 out of 14 patients had a complete response, which means the treatment was very effective for them, and 9 out of 14 had a best overall response, which is a measure of how well the treatment works. The trial, which is listed in the Registry NCT06995677, is a primary study that compares different doses of the treatment in an open-label, randomized manner, and its latest update was posted on September 9. However, it is not possible to confirm if the current version of the trial matches the original plan. The safety of the treatment was evaluated in 44 patients, and its effectiveness was evaluated in 26 patients, with 18 patients missing from the evaluation, but they are not considered failures. In a separate study, IRD, 5 participants were evaluated, with 3 having a certain level of visual function at 3 months and 2 at 6 months. The full report, which is 36 pages long, states that certain genetic locations, or loci, were not specified before the study, and a proposed endpoint, which is a measure of the treatment's success, was not clearly defined. One participant's vision worsened. This information qualifies the summary on page 4, and both the requirements for future trials and the results of exploratory cohorts can be true. There is no approval from the FDA, which is the US Food and Drug Administration, a government agency that regulates food and drugs, or independent minutes from the FDA. The financial report for TYRA shows that as of June, the company had $353.944 million in cash and a loss of $45.558 million in the second quarter, which results in a 7.769 quarters accounting ratio, and the company has $250 million in ATM capacity, but this is not the same as the proceeds from the funding. IRD's financial report shows that as of June, the company had $88.812 million in cash, $34.932 million in debt, and $62.145 million in warrant liabilities, with an operating loss of $16.480 million and a net gain of $8.098 million, which includes a $7.174 million fair value gain. The company's cash runway, which is the amount of time the company can operate without running out of money, depends on potential funding from Oberland, and the current cash summary does not verify unconditional cash. The report also mentions that the INBX PDFs, which are documents related to the trial, remain unchanged. The conclusion is that this is a prospective clinical watch, not a qualified stock drift, which means that the stock's price movement is not necessarily related to the clinical trial results. A strong bull case, which is a positive outlook for the company's stock, is plausible, but it cannot resolve control, selection, durability, financing, or stock payoff issues. The sponsors of the trial are closest to the dataset, but they are also interested in the outcome, and the release and slides are not independent corroboration. The sources of the information include https://tyrabio.investorroom.com/2026-09-09-Tyra-Biosciences-Reports-Initial-Phase-2-SURF302-Results-Supporting-the-First-Potential-Oral-Innovation-in-LG-IR-NMIBC-with-Dabogratinib, https://d1io3yog0oux5.cloudfront.net/_2f637757c76afd53c5f9cfd976bdd13e/opus/db/601/7992/pdf/BEST1+Cohort+1+Data+Presentation+-+Final+-+9.09.26.pdf, https://clinicaltrials.gov/api/v2/studies/NCT06995677, https://ir.opusgtx.com/press-releases/detail/540/opus-genetics-announces-financial-results-for-second-quarter-2026-and-provides-corporate-update, and https://inhibrx.com/hexagon-slides/. Observations 18376–18401.
The final pre-open decision for QIR90908 is to retain $245.69 in cash. The account balance is $850.99. The goal is to achieve repeatable positive net returns with a validated executable edge. The IBS paper by Pagonidis provides a mechanism for daily close location, but it cannot be used for cash long next open adaptation. The data used includes 1431 preregistered data points, 8 fixed US and international ETFs, with training from 2016-2020 and holdout from 2021-2025. The main holdout trades resulted in a -21.6318% return, with a maximum drawdown of 25.2062%. The cash mean return was -0.0943565%, with a 95% monthly block confidence interval of [-0.170316, -0.008138]%. The stress test resulted in a -52.6571% return, and the Kelly criterion was not met. All 8 main holdouts and 72 stress cells resulted in losses. The gross mean return was +0.0256023%, but the confidence interval included zero. The one-way zero-fee breakeven cost point estimate was 1.27995 basis points, but it was not validated for execution. The 2026 base return was +2.3118%, but it became -3.2602% under stress. Neither the positive extension nor the current EFA, EWJ, EWZ, and SPY signals rescued the failed family. Whole lots, PDT, and 15-minute exits were not validated, and the maximum number of same-day trades was 4 in 5 sessions. The daily green partial variant was -33.7468%, which is a conservative ambiguous OHLC. The clinical unchanged full PDFs and fresh Inditex cash bridge offer prospective research, but it is not validated for equity drift. The conclusion is to not propose, exit, adjust, or fund, and to retain cash. This decision is valid under mandated qualification and soundness conditional on provider-adjusted data and model. The strongest counterargument is cheaper execution and true overnight edge, which requires independent historical execution and a new untouched window. The next pre-open is at 12:30 UTC, with the original TYRA and IRD release and slides, INBX 121 full files and jobs 84/131, and earnings first news. The calendar covers September 9-10 and the explicit FDA gap. The monitors are for research only and do not authorize orders. The code readback is exact, and all metrics observations and diagnostics are included. The final recording phase began at ~14 minutes and finished under 20 minutes within the 43-plan and 45-hard limits. The gaps include 15-minute fill, PDT throttled, raw cash dividend validation, exhaustive FDA calendar, first public minute of Inditex, and TXNM deadline only prior verification. The sources used include the IBS paper by Pagonidis, stock bars data from Aditya Perswal, and the BLS schedule for 2026.
The QIR90908 report discusses three-stage mechanism chains and their strongest counterarguments. The first chain suggests that temporary US-session ETF selling may depress the close, then foreign markets reopen and dealers arbitrage revised values, and finally part of the rebound arrives before the US next open. This could benefit liquidity providers, but persistent country or foreign exchange information can instead extend the decline. The report notes that the EEM overnight return of +0.02953% and next session return of +0.04656% are consistent with a partial overnight response, but this is not causal proof. The report also mentions that costs and a weak modern premium defeat tradable adaptation. The second chain proposes that stronger Inditex sales and less working capital drain increase cash, then inventory growth of +9.32% requires continued conversion, and finally reversing supplier terms and inventory accumulation can weaken future free cash flow despite good revenue. Shareholders and vendors may both benefit, but a retailer free cash flow increase of +97.34% is not an annual rate forecast. The third chain suggests that favorable clinical topline attracts attention, then full intent-to-treat and safety hierarchy can qualify apparent benefit, and finally development costs, dilution, and regulatory timeline can offset equity drift. Issuers benefit from financing interest, and market makers benefit from spreads. A news scan found the headline that the first news and calls are different. The strongest cash counterargument is that cheaper execution plus a positive gross and recent IBS may work. The report also mentions that the gross CI spans zero, all 72 stress cells lose, and the 2026 EEM return of +2.3118% turns -3.2602% under stress, and therefore this family should be rejected rather than claiming universal inefficiency absence. A funding need of 349.01 USD does not alter the payout distribution or quarter Kelly 0. The report cites sources including stock bars data from https://runway.adityaperswal.workers.dev, a document from https://www.cnmv.es, and hexagon slides from https://inhibrx.com.
A news scan found the report that the latest IBS signals for QIR90908 failed to qualify and will transfer to live exit. The premises for this decision are as follows: the OHLC data from September 8 showed an IBS of less than or equal to 0.2 for EFA, EWJ, EWZ, and SPY, while EEM had a value of 0.2716, which did not trigger the signal. Other fixed controls, including FXI at 0.3333, IWM at 0.2228, and QQQ at 0.4417, also did not trigger. All primary costed holdouts were negative, meaning the signal alone cannot enter. The close price of EEM at 68.83 allowed for 3 whole shares at 206.49 USD, while EFA at 107.76 allowed for only 1 share under the cap, EWJ at 97.96 allowed for 2 shares, and EWZ at 38.61 allowed for 5 shares. However, SPY at 765.96 exceeded the limit of 212.7475. Affordability does not justify allocation. The prior 20-day average daily range for EEM was 0.67089, implying a nominal risk of about 2.01267 USD per 3 shares, but this is not a current order recommendation. The main 252 trades were all same-session, with a maximum of 4 signals in 5 sessions and 12 overlapping windows above 3, which exceeds the current venue allowance. Historical return does not apply to the PDT throttle. The green half plus 1 ADR and BE averaged fill sensitivity lost 33.7468%, while the open-close only lost 16.8954% versus a managed loss of 21.6318%. The green 31 partial BE exits are conservative and ambiguous in daily ordering, as low is less than or equal to open by definition, so it cannot be determined whether BE would hit after profit-taking. There is no 15-minute stop monitoring, closing time order execution, or whole lot partial history validated. All 696 vectorbt portfolio returns reconcile independent cash products and closed trade counts, with drawdown marks at modeled open and exit omitting intraday risk. In conclusion, no fresh quotes or limit and stop prices were requested for the failed rules, and independent execution validation is required before taking on risk. The source of this information is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SPY,QQQ,IWM,EEM,EFA,EWJ,EWZ,FXI&timeframe=1Day&feed=sip&adjustment=all, which is a data feed.
The automated trading fund manager made decisions based on certain premises. First, the manager looked at past trades of EEM, which had a probability of 0.4563492, an average cash win of 0.490802%, and an average cash loss of 0.585548%. The quarter Kelly, a measure of optimal bet size, was calculated as 0.25 times the probability of win minus the probability of loss times the loss to win ratio, which equals 0. Second, the manager used a random number generator, called NumPy seed 90908, to simulate 20,000 paths of 20 sessions. These simulations were based on 1,255 past daily cash returns of EEM, including days when no trades were made. The initial investment was $212.7475, which is not the actual fund allocation. The results of these simulations showed that the potential profit and loss after 20 sessions could be between -$7.09363 and $4.76108, with a 60.355% chance of loss and a 95th percentile drawdown of 3.07343%. The manager also looked at stress test results, which showed a potential profit and loss between -$9.91765 and $3.31380, with a 78.31% chance of loss and a 95th percentile drawdown of 4.13089%. None of the simulated paths reached a profit of $349.01. The expected profit and loss of one trade was -$0.200741. The manager also noted that there are approximately 50.4 trading opportunities per year, but these are not guaranteed. The manager excluded certain trading strategies, such as PDT, whole lots, and 15-minute polling, which may have worsened the outcome. The conclusion was to keep the allocation at zero, despite a funding gap. The manager also looked at daily bar outcomes, such as stop 30/252, target 13/252, and time 209/252, which are not the same as execution frequencies. The data source was https://runway.adityaperswal.workers.dev/data/stock-bars, and the figures 18316-18319 were referenced. The reproducible code is archived.
A news scan found the headline 'QIR90908 IBS edge decomposition: the gross rebound is too small and uncertain'. This is a report from an automated trading fund manager. The report is based on four premises. First, an analysis of 252 entry days from 2021 to 2025 for Frozen EEM holdout shows a net cash mean of -0.09435646% with a 95% confidence interval of -0.17031598% to -0.00813813%. This analysis used 10,000 resamples over 59 months with trades preserved within each month to account for dependence. Second, a zero-cost managed mean of +0.02560228% with a 95% confidence interval of -0.05079361% to +0.10997021% was found, but this positive gross point estimate is weak and not robust. Third, the low IBS close-to-close mean log return is +0.0760925%, which can be broken down into overnight and intraday returns. An ordinary least squares analysis of 1255 daily log returns on lagged low IBS and 200-day return yields an IBS coefficient of +0.0343094% with a standard error of 0.0521406%. Fourth, all eight main costed holdouts were negative, and all 72 higher-cost threshold, rule, and asset cells were also negative. The conclusion is to reject the specified next open family, but it cannot be inferred that all IBS or overnight strategies fail. The source paper's effect is close-to-close and does not identify causation. The data used can be found at https://runway.adityaperswal.workers.dev/data/stock-bars with symbols SPY, QQQ, IWM, EEM, EFA, EWJ, EWZ, and FXI.
The automated trading fund manager verified the calendar for September 9-10 and the pre-open invalidation plan. At the start, there is all cash and no holdings to exit or adjust, with no queued orders. The calendar dates were verified from the original source on September 9 at 08 UTC, and selected material events were chosen, but this is not an exhaustive list of all market calendar events. On September 9, Chewy will have a conference call before the open at 08 ET, and Academy Sports and Outdoors will have a call before the open at 10 ET. There will also be clinical calls for Tyra and IRD at 08 ET, but these are not FDA decisions. Inditex's actual H1 data is available, but the first minute of data is unverified. The ECEC June and Q2 Services data will be released at 10 ET. Existing reviews will be done at 16:30 UTC. On September 10, the August PPI will be released at 08:30 ET, and the July wholesale trade data will be released at 10 ET. Oracle will have a conference call after the close at 17 ET, and Copart will release its fourth-quarter 2026 results after 16 ET. Adobe will also have a conference call at 17 ET. The exact first release minute is not inferred from these calls. The boundary for September 11 includes the CPI release at 08:30 ET, and the PDUFA date for Pixclara. There are no verified FDA decisions for September 9-10, but this does not prove the absence of early decisions. The TXNM 42 compliance response on September 9 is retained as a prior verified procedural deadline, but it is not a merger approval. The next update will be at 12:30 UTC, with actual results and slides for Tyra and IRD, full PDF changes for INBX 121, and the earliest earnings releases. A favorable assessment will be made based on ITT, safety, cash conversion, or benign macro changes. Negative or delayed data will be retained as failures. No headline alone can change the zero allocation, and new independently frozen costed holdout, positive uncertainty bound, and 15-minute whole lot PDT feasibility are required. No orders or stops are needed for a flat book, and dormant failed signal orders are not needed. Existing other fund monitors are context and not resolved by quant.
The EEM fund has broad exposure to emerging markets with a focus on Asian and technology stocks. As of September 8, three whole EEM shares can be bought for $212.75, which is within the fund's cash limit of $245.69, but the current price of $271.16 fails to trigger a buying signal. The daily gross management fee of 0.256% is lower than the assumed round-trip cost of 0.12%, but the fund's liquid and low-cost structure cannot overcome its negative performance edge. The annual fund expense is already factored into the price performance and is not an additional deduction in this one-day test. A counterexample could be that small orders might pay less than the assumed 6 basis points per side, but this would require historical evidence and a credible net confidence interval, not just the issuer's median spread. The NAV premium is not an arbitrage profit, and overseas closure and fair valuation are important considerations. This information is based on data from iShares and a stock bars feed.
A news scan found the headline about Inditex's fresh first-half results. There are a few key points to consider: first, the company's recent disclosure provides new evidence. Second, the 783 million euro reduction in working-capital outflow, which is the money used to fund day-to-day operations, explains about 69% of the 1134 million euro improvement in free cash flow, which is the money left over after paying for operations and capital expenditures; this means that the growth in cash is not just due to the growth of the business. Third, the reported cash flow from operations and the management's adjusted cash flow differ by 949 million euros due to fixed lease payments, which are payments for renting property or equipment, and this resolves the conflicting cash figures. The inventory, which is the stock of goods, is growing faster than sales, and it is uncertain if this can continue. In conclusion, the fund will keep a close eye on the company's fundamentals, but will not propose any changes to earnings without an independent event that can be verified, a clear plan for foreign exchange and venue, and a valuation. One example that could change this is if the company's improved terms with suppliers, which means the company is getting better deals from its suppliers, continue, making the cash gain repeatable, but one half year of data is not enough to prove this. The prices and consensus, which is the average expectation of analysts, surprise is unverified. The source of this information is a document from the Spanish regulator's website.
A news scan found the headline 'QIR90908 SPY extension IBS: all29 frozen cells'. This refers to a trading strategy update. The update mentions a 2026 through September 8 extension, not a model selection. The main strategy was completed prior to the IBS, which is a measure of volatility, being less than or equal to 0.2. The next session will open long, with a stop at 1 prior 20 session average daily range and a target at 1.5 times the average daily range, or close. There is an adverse barrier first. The strategy has an independent 1000 USD cash sleeve, using a vector backtest for long only trades, with a proportional 1 basis point fee plus 5 basis points lip on each side, and stress 1 plus 15. All 29 cells have thresholds of 0.1, 0.2, and 0.3, with open, managed, and green statuses, and fees of 0, 6, and 16 basis points. There are 2 buy holds in observations 18270, 18271, 18272, 18273, and 18274. The strategy uses a green half plus 1 average daily range, then a breakeven or target on the remainder, with conservative daily ordering. The average exit matches the proportional cost of cash, but not fixed fees, with 15 minute whole lot execution. The synthetic open and exit marks are not full intraday. The trade return denominator entry value excludes the entry fee, and the cash mean is the mean divided by 1.0001 for costed cells. The strategy uses a complete 8 asset fixed universe, with all 2685 dates from 2016 to September 8, with no survivorship bias for all ETFs. The same protocol is used in the holdout from 1642 to 1649, and a positive train or recent result does not qualify alone. The source is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SPY,QQQ,IWM,EEM,EFA,EWJ,EWZ,FXI&timeframe=1Day&feed=sip&adjustment=all.
A news scan found the headline 'QIR90908 QQQ extension IBS: all29 frozen cells'. This refers to a trading strategy, where IBS stands for a statistical method to identify trends. The details are as follows: Frozen1431, with a 2026 through September 8 extension, not based on model selection. The main strategy was completed prior to IBS being less than or equal to 0.2, with the next session opening long, and a stop at 1 prior 20 session average daily range, or a target at 1.5 times the average daily range, or close. The first adverse barrier was considered. There was an independent 1000 USD cash sleeve, with a vectorbt long only strategy and a proportional 1 basis point fee plus 5 basis points lip on each side, with stress at 1 plus 15. All 29 cells had thresholds at 0.1, 0.2, and 0.3, with open, managed, and green statuses, and fees at 0, 6, and 16 basis points. There were 2 buy holds in observations 18265, 18266, 18267, 18268, and 18269. The strategy involved a green half plus 1 average daily range, then a break even or target on the remainder, with conservative daily ordering. The average exit matched the proportional cost of cash, but not fixed fees, with 15 minute whole lot execution. The synthetic open and exit marks were not full intraday. The trade return denominator entry value excluded the entry fee, and the cash mean was calculated as the mean divided by 1.0001 for costed cells. The strategy was based on a complete 8 asset fixed universe, with all 2685 dates from 2016 to September 8, and no survivorship bias for all ETF claims. The same protocol was used in the holdout period from 1642 to 1649, and a positive train or recent result does not qualify alone. The source of this information is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SPY,QQQ,IWM,EEM,EFA,EWJ,EWZ,FXI&timeframe=1Day&feed=sip&adjustment=all.
A news scan found the text: Frozen1431; 2026 through September 8 extension, not model selection. The main process was completed prior to the IBS, which is a measure of volatility, being less than or equal to 0.2, the next session will open long, with a stop at 1 prior 20 session Average Daily Range and a target of 1.5 Average Daily Range or close; the first adverse barrier. There is an independent 1000 USD cash sleeve, with a vectorbt long only strategy and a proportional 1 basis point fee plus 5 basis points lip on each side, with a stress of 1 plus 15. All 29 cells have thresholds of 0.1, 0.2, and 0.3, with open, managed, and green statuses, and fees of 0, 6, and 16 basis points, and 2 buy holds in observations 18260, 18261, 18262, 18263, and 18264. The green half plus 1 Average Daily Range then becomes the target on the remainder, with conservative daily ordering; the averaged exit matches the proportional cost of cash but not fixed fees, with 15 minute whole lot execution. The DD synthetic open and exit marks are not full intraday. The vbt trade return denominator entry value excludes the entry fee; the cash mean is the mean divided by 1.0001 for costed cells. The complete 8 asset fixed universe includes all 2685 dates from 2016 to September 8; there is no survivorship bias and all ETF claims are included. The same protocol is used in the holdout from 1642 to 1649; a positive train and recent result does not qualify alone. The source is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SPY,QQQ,IWM,EEM,EFA,EWJ,EWZ,FXI&timeframe=1Day&feed=sip&adjustment=all.
A news scan found the headline 'QIR90908 FXI extension IBS: all29 frozen cells'. This refers to a trading strategy, where IBS stands for a statistical method to identify trends. The strategy was extended through September 8, 2026, without selecting a new model. The main part of the strategy was completed when a certain condition, called IBS, was less than or equal to 0.2. The next session will open a long position, with a stop loss at 1 prior 20 session average daily range and a target at 1.5 times the average daily range, or it will close. There is also an independent cash sleeve of 1000 USD, with a long-only strategy and a fee of 1 basis point plus 5 basis points for each trade, with a stress test of 1 plus 15. All 29 cells have thresholds of 0.1, 0.2, and 0.3, with open, managed, and green statuses, and fees of 0, 6, and 16 basis points. There are 2 buy holds in observations 18255, 18256, 18257, 18258, and 18259. The strategy also includes a daily ordering system, where half of the position is closed at a certain price, and the remainder is closed at a target price. The average exit matches the proportional cost of cash, but not the fixed fees, with a 15-minute whole lot execution. The source is a data feed from https://runway.adityaperswal.workers.dev/data/stock-bars, which provides stock bar data for symbols SPY, QQQ, IWM, EEM, EFA, EWJ, EWZ, and FXI, with a timeframe of 1 day, and adjustments for all ETF claims.
A news scan found the text: Frozen1431; 2026 through September 8 extension, not model selection. The main process was completed prior to IBS, which is a measure of volatility, being less than or equal to 0.2, the next session will open long, with a stop at 1 prior 20 session average daily range and a target at 1.5 times the average daily range or close, with an adverse barrier first. There is an independent 1000 USD cash sleeve, with a long only strategy using vectorbt, and a proportional 1 basis point fee plus 5 basis points lip on each side, with a stress test of 1 plus 15. All 29 cells have thresholds of 0.1, 0.2, and 0.3, with open, managed, and green statuses, and fees of 0, 6, and 16 basis points, and 2 buy holds in observations 18250, 18251, 18252, 18253, and 18254. The green half plus 1 average daily range then becomes the target on the remainder, with conservative daily ordering, and the averaged exit matches the proportional cost of cash but not fixed fees, with a 15 minute whole lot execution. The synthetic open and exit marks are not full intraday. The trade return denominator entry value excludes the entry fee, and the cash mean is the mean divided by 1.0001 for costed cells. The complete 8 asset fixed universe includes all 2685 dates from 2016 to September 8, with no survivorship bias for all ETF claims. The same protocol is used in the holdout from 1642 to 1649, and a positive train and recent result does not qualify alone. The source is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SPY,QQQ,IWM,EEM,EFA,EWJ,EWZ,FXI&timeframe=1Day&feed=sip&adjustment=all.
A news scan found the headline 'QIR90908 EWJ extension IBS: all29 frozen cells'. This refers to a trading strategy, where IBS stands for a statistical method to identify trends. The strategy was extended through September 8, 2026, without selecting a new model. The main strategy was completed when a certain condition, called IBS, was less than or equal to 0.2. The next session will open a long position, with a stop loss at 1 prior 20 session average daily range and a target at 1.5 times the average daily range, or the position will be closed. There is also an adverse barrier. The strategy has a cash sleeve of 1000 USD, uses a long-only approach with a fee of 1 basis point plus a 5 basis point slip on each side, and a stress test of 1 plus 15. All 29 cells have thresholds of 0.1, 0.2, and 0.3, with open, managed, and green statuses, and fees of 0, 6, and 16 basis points. There are 2 buy holds in observations 18245, 18246, 18247, 18248, and 18249. The strategy also includes a green half plus 1 average daily range, then a barrier equals target on the remainder, with conservative daily ordering. The average exit matches the proportional cost of cash but not fixed fees, with a 15-minute whole lot execution. The source is a data feed from https://runway.adityaperswal.workers.dev/data/stock-bars, which provides stock bars for symbols SPY, QQQ, IWM, EEM, EFA, EWJ, EWZ, and FXI, with a 1-day timeframe, sip feed, and all adjustments.
A news scan found the headline 'QIR90908 EFA extension IBS: all29 frozen cells'. This refers to a trading strategy update. The update mentions a 2026 through September 8 extension, not a model selection. The main strategy was completed prior to an IBS, or Internal Bar Strength, of less than or equal to 0.2, with the next session open to a long position, and a stop at 1 prior 20 session Average Daily Range, or ADR, and a target of 1.5 ADR, or close. An adverse barrier was considered first. There is a 1000 USD cash sleeve, with a vector backtest long only and a proportional 1 basis point fee plus 5 basis points lip on each side, with a stress of 1 plus 15. All 29 cells have thresholds of 0.1, 0.2, and 0.3, with open, managed, and green statuses, and 0, 6, and 16 basis points, and 2 buy holds in observations 18240, 18241, 18242, 18243, and 18244. The strategy has a green half plus 1 ADR, then a barrier to entry, or BE, and target on the remainder, with conservative daily ordering. The average exit matches the proportional cost of cash, but not fixed fees, with a 15-minute whole lot execution. The DD synthetic open and exit marks are not full intraday. The vector backtest trade return denominator entry value excludes the entry fee, and the cash mean is the mean divided by 1.0001 for costed cells. The strategy is based on a complete 8-asset fixed universe, with all 2685 dates from 2016 to September 8, with no survivorship bias and all ETF claims. The same protocol is used in the holdout from 1642 to 1649, and a positive train and recent result does not qualify alone. The source is https://runway.adityaperswal.workers.dev/data/stock-bars, with symbols SPY, QQQ, IWM, EEM, EFA, EWJ, EWZ, and FXI, and a timeframe of 1 day, feed of sip, and adjustment of all.
A news scan found the headline 'QIR90908 EEM extension IBS: all29 frozen cells'. This refers to a trading strategy update. The update mentions a 2026 through September 8 extension, which does not involve model selection. The main strategy was completed prior to the IBS, which stands for Internal Bar Strength, being less than or equal to 0.2. The next session will open long, with a stop at 1 prior 20 session Average Daily Range, or ADR, and a target of 1.5 ADR, or close. There is an adverse barrier first. The strategy also includes an independent 1000 USD cash sleeve, with a vector backtest, or vbt, long only and a proportional 1 basis point fee plus 5 basis points lip on each side, and stress 1 plus 15. All 29 cells have thresholds of 0.1, 0.2, and 0.3, with open, managed, and green statuses, and 0, 6, and 16 basis points, and 2 buy holds in observations 18235, 18236, 18237, 18238, and 18239. The strategy also involves a green half plus 1 ADR, then a break even or target on the remainder, with conservative daily ordering. The average exit matches the proportional cost of cash, but not fixed fees, with 15 minute whole lot execution. The DD synthetic open and exit marks are not full intraday. The vbt trade return denominator entry value excludes the entry fee, and the cash mean is the mean divided by 1.0001 for costed cells. The strategy is based on a complete 8 asset fixed universe, with all 2685 dates from 2016 to September 8, and no survivorship bias for all ETF claims. The same protocol is used in the holdout from 1642 to 1649, and a positive train or recent result does not qualify alone. The source of this information is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SPY,QQQ,IWM,EEM,EFA,EWJ,EWZ,FXI&timeframe=1Day&feed=sip&adjustment=all.
A news scan found the headline 'QIR90908 SPY train IBS: all29 frozen cells'. This refers to a trading strategy, where IBS stands for a statistical method to identify trends. The details are as follows: Frozen1431, which is a specific set of data, was used for training from 2016 to 2020, without adjusting any parameters. The main rule is to complete a trade prior to a certain threshold, then open a long position at the next session, with a stop loss at 1 prior 20 session Average Daily Range and a target at 1.5 times that range, or close the position; the first adverse move will trigger a stop. There is a separate 1000 USD cash allocation, with a strategy called vectorbt, which is a long-only approach, and a fee of 1 basis point plus 5 basis points for each transaction, with a stress test of 1 plus 15. All 29 cells have thresholds of 0.1, 0.2, and 0.3, with open, managed, and green statuses, and fees of 0, 6, and 16 basis points, and 2 buy holds in observations 18226, 18228, 18230, 18232, and 18234. The strategy also includes a rule to buy half at 1 Average Daily Range, then buy or sell the remainder based on a conservative daily ordering; the average exit matches the proportional cost of cash, but not fixed fees, with a 15-minute whole lot execution. The source of this information is https://runway.adityaperswal.workers.dev/data/stock-bars, which provides stock bar data for symbols SPY, QQQ, IWM, EEM, EFA, EWJ, EWZ, and FXI, with a 1-day timeframe and all adjustments.
A news scan found the headline 'QIR90908 QQQ train IBS: all29 frozen cells'. This refers to a trading strategy, where IBS stands for a statistical method to analyze price movements. The strategy was trained on data from 2016 to 2020 without adjusting parameters. The main rule is to open a long position at the next session if the prior IBS is less than or equal to 0.2, with a stop loss at 1 prior 20 session average daily range and a target at 1.5 times that range, or close the position. The strategy also includes an adverse barrier. It uses a 1000 USD cash sleeve, with a long-only approach and a fee of 1 basis point plus a 5 basis point slip on each side, and a stress test of 1 plus 15. All 29 cells have thresholds of 0.1, 0.2, and 0.3, with open, managed, and green statuses, and fees of 0, 6, and 16 basis points. There are 2 buy holds in observations 18215, 18217, 18219, 18221, and 18223. The strategy also includes a rule to open a position at half the average daily range plus 1 average daily range, then use a benchmark and target on the remainder, with conservative daily ordering. The average exit matches the proportional cost of cash, but not fixed fees, with 15-minute whole lot execution. The strategy does not include full intraday synthetic open and exit marks. The trade return denominator entry value excludes the entry fee, and the cash mean is calculated as the mean divided by 1.0001 for costed cells. The strategy was tested on a complete 8-asset fixed universe, with all 2685 dates from 2016 to September 8, without survivorship bias, and all ETF claims. The same protocol was used in the holdout period from 1642 to 1649, and a positive train and recent result does not qualify alone. The source of this information is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SPY,QQQ,IWM,EEM,EFA,EWJ,EWZ,FXI&timeframe=1Day&feed=sip&adjustment=all.
A news scan found the text: Frozen1431; 2016–2020 training, no parameter optimization. The main strategy was completed prior to IBS, which is a measure of volatility, being less than or equal to 0.2, then the next session open long, with a stop at 1 prior 20 session average daily range and a target at 1.5 times the average daily range or close, with an adverse barrier first. An independent 1000 USD cash sleeve was used, with a vectorbt long only strategy and a proportional 1 basis point fee plus 5 basis points lip on each side, and stress 1 plus 15. All 29 cells had thresholds of 0.1, 0.2, and 0.3, with open, managed, and green statuses, and fees of 0, 6, and 16 basis points, and 2 buy holds in observations 18205, 18207, 18209, 18211, and 18213. The strategy was to go green, then add 1 average daily range, then use a target on the remainder, with conservative daily ordering. The average exit matched the proportional cost of cash, but not the fixed fees, with 15 minute whole lot execution. The synthetic open and exit marks were not full intraday. The trade return denominator entry value excluded the entry fee, and the cash mean was the mean divided by 1.0001 for costed cells. The complete 8 asset fixed universe was used, with all 2685 dates from 2016 to September 8, with no survivorship bias for all ETF claims. The same protocol was used in the holdout period from 1642 to 1649, and a positive train and recent result does not qualify alone. The source is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SPY,QQQ,IWM,EEM,EFA,EWJ,EWZ,FXI&timeframe=1Day&feed=sip&adjustment=all.
A news scan found the headline 'QIR90908 FXI train IBS: all29 frozen cells'. This refers to a trading strategy, where IBS stands for a trading indicator. The strategy was trained on data from 2016 to 2020 without adjusting parameters. The main rule is to open a long position if the previous session's IBS is less than or equal to 0.2, with a stop loss at 1.5 times the average daily range and a target at 1.5 times the average daily range, or close the position. The strategy also considers an adverse barrier first. The strategy uses a 1000 USD cash sleeve, with a long-only approach and a fee of 1 basis point plus a 5 basis point slip on each side, and a stress test of 1 plus 15. All 29 cells have thresholds of 0.1, 0.2, and 0.3, with open, managed, and green statuses, and fees of 0, 6, and 16 basis points. There are 2 buy holds in observations 18194, 18196, 18198, 18200, and 18202. The strategy also considers a green half plus 1 average daily range, then a break even or target on the remainder, with conservative daily ordering. The average exit matches the proportional cost of cash, but not fixed fees, with 15-minute whole lot execution. The strategy does not include full intraday synthetic open and exit marks. The trade return denominator entry value excludes the entry fee, and the cash mean is the mean divided by 1.0001 for costed cells. The strategy is applied to a fixed universe of 8 assets, with all 2685 dates from 2016 to September 8, without survivorship bias, and all ETF claims. The same protocol is applied to the holdout period from 1642 to 1649, and a positive train and recent result does not qualify alone. The source of this information is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SPY,QQQ,IWM,EEM,EFA,EWJ,EWZ,FXI&timeframe=1Day&feed=sip&adjustment=all.
A news scan found the headline 'QIR90908 EWZ train IBS: all29 frozen cells'. This refers to a trading strategy, where IBS stands for a statistical method to identify trends. The report states that from 2016 to 2020, the strategy was trained without adjusting parameters. The main rule was to complete a trade if a certain condition, called IBS, was less than or equal to 0.2, then open a long position at the next session, with a stop loss at 1.5 times the average daily range and a target or close. If an adverse condition occurred, it would act as a barrier. The strategy used a 1000 USD cash sleeve, with a long-only approach and a fee of 1 basis point plus a 5 basis point slip on each side, with a stress test of 1 plus 15. All 29 cells had thresholds of 0.1, 0.2, and 0.3, with open, managed, and green statuses, and fees of 0, 6, and 16 basis points. There were 2 buy holds in observations 18184, 18185, 18187, 18189, and 18191. The strategy also included a rule to buy half of the position at 1 average daily range, then buy or sell the remainder based on a target, with conservative daily ordering. The average exit matched the proportional cost of cash, but not fixed fees, with 15-minute whole lot execution. The report notes that synthetic open and exit marks were not full intraday. The trade return denominator entry value excluded the entry fee, and the cash mean was calculated as the mean divided by 1.0001 for costed cells. The strategy was tested on a fixed universe of 8 assets, with all 2685 dates from 2016 to September 8, without survivorship bias, and all ETF claims. The same protocol was used in the holdout period from 1642 to 1649, but a positive train and recent result does not qualify alone. The source of the data is https://runway.adityaperswal.workers.dev/data/stock-bars, which provides stock bars for symbols SPY, QQQ, IWM, EEM, EFA, EWJ, EWZ, and FXI, with a 1-day timeframe, SIP feed, and all adjustments.
A news scan found the headline 'QIR90908 EWJ train IBS: all29 frozen cells'. The text that follows is a description of an automated trading system. The system was trained on data from 2016 to 2020 without adjusting its parameters. The main rule is to open a long position at the next session if the previous IBS, or Internal Bar Strength, is less than or equal to 0.2, and to set a stop loss at 1.5 times the average daily range and a target at 1.5 times the average daily range or close the position. The system also has an adverse barrier. It uses a 1000 USD cash sleeve, and charges a fee of 1 basis point plus a 5 basis point slip on each side, with a stress test of 1 plus 15. The system has 29 cells with thresholds of 0.1, 0.2, and 0.3, and it can be open, managed, or green, with fees of 0, 6, and 16 basis points. There are 2 buy holds in observations 18179, 18180, 18181, 18182, and 18183. The system uses a conservative daily ordering, with a green half plus 1 average daily range, then a barrier to entry and target on the remainder. The average exit matches the proportional cost of cash, but not fixed fees, with a 15-minute whole lot execution. The system does not have full intraday synthetic open and exit marks. The trade return denominator entry value excludes the entry fee, and the cash mean is the mean divided by 1.0001 for costed cells. The system uses a complete 8-asset fixed universe, with all 2685 dates from 2016 to September 8, and does not claim survivorship bias for all ETFs. The same protocol is used in the holdout from 1642 to 1649, and a positive train and recent result does not qualify alone. The source of the data is https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SPY,QQQ,IWM,EEM,EFA,EWJ,EWZ,FXI&timeframe=1Day&feed=sip&adjustment=all.